A faster and vastly more effective treatment for drug-resistant tuberculosis is being rolled out in the Asia-Pacific region, raising hopes of a "new era" in tackling one of the world's deadliest infectious diseases.
Apr 12, 2024
0
20
Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers ...
Feb 27, 2024
0
3
Researchers have identified new antibiotic molecules that target Mycobacterium tuberculosis and make it less pathogenic for humans. In addition, some of the discovered substances may allow for a renewed treatment of tuberculosis ...
Jan 4, 2024
0
49
A proportion of patients with drug-resistant tuberculosis (TB) receive ineffective treatment due to misdiagnosis by rapid molecular tests, according to a genomic analysis carried out in southern Mozambique and co-led by the ...
Dec 4, 2023
0
8
With one of the highest tuberculosis (TB) incidences (368 cases/100,000 population) in the African region, Mozambique is particularly affected by the TB epidemic. Drug-resistant TB is also a major problem, with 4,800 new ...
Nov 13, 2023
0
36
Tuberculosis is often seen as a threat of the past. But it remains a significant concern worldwide, with international travel spreading the disease.
Oct 16, 2023
0
0
Tuberculosis (TB) is a curable and preventable infectious disease. And yet, more than 10 million people fall ill with it every year, and more than 1.5 million people die.
Jul 10, 2023
0
2
A multidisciplinary group of tuberculosis experts from the TBnet and RESIST-TB networks have reached a consensus on key issues related to the molecular prediction of Mycobacterium tuberculosis antibiotic sensitivity or resistance ...
Apr 14, 2023
0
9
Volodymyr is celebrating a major milestone on Wednesday—it's his final day of taking a new treatment hailed as a turning point in the fight against drug-resistant tuberculosis.
Sep 1, 2022
0
47
A massive analysis of more than 10,000 different Mycobacterium tuberculosis bacteria isolates from 23 countries has revealed new genes associated with resistance to 13 first- and second-line new and repurposed antibiotics. ...
Aug 10, 2022
0
124
Active tuberculosis will kill about two of every three people affected if left untreated. Treated tuberculosis has a mortality rate of less than 5%.
The standard "short" course treatment for tuberculosis (TB), is isoniazid, rifampicin, pyrazinamide, and ethambutol for two months, then isoniazid and rifampicin alone for a further four months. The patient is considered cured at six months (although there is still a relapse rate of 2 to 3%). For latent tuberculosis, the standard treatment is six to nine months of isoniazid alone.
If the organism is known to be fully sensitive, then treatment is with isoniazid, rifampicin, and pyrazinamide for two months, followed by isoniazid and rifampicin for four months. Ethambutol need not be used.
This text uses material from Wikipedia, licensed under CC BY-SA
